Royalty Pharma plc (RPRX)
- Previous Close
28.09 - Open
28.26 - Bid 28.37 x 800
- Ask 28.41 x 800
- Day's Range
28.10 - 28.56 - 52 Week Range
25.92 - 34.65 - Volume
1,949,099 - Avg. Volume
2,824,145 - Market Cap (intraday)
16.955B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
15.94 - EPS (TTM)
1.78 - Earnings Date Aug 6, 2024 - Aug 12, 2024
- Forward Dividend & Yield 0.84 (2.99%)
- Ex-Dividend Date May 16, 2024
- 1y Target Est
45.33
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
www.royaltypharma.comRecent News: RPRX
Performance Overview: RPRX
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RPRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RPRX
Valuation Measures
Market Cap
12.67B
Enterprise Value
17.27B
Trailing P/E
15.78
Forward P/E
8.26
PEG Ratio (5yr expected)
1.17
Price/Sales (ttm)
7.53
Price/Book (mrq)
1.95
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
35.69%
Return on Assets (ttm)
3.54%
Return on Equity (ttm)
12.06%
Revenue (ttm)
2.24B
Net Income Avi to Common (ttm)
798.86M
Diluted EPS (ttm)
1.78
Balance Sheet and Cash Flow
Total Cash (mrq)
872M
Total Debt/Equity (mrq)
62.24%
Levered Free Cash Flow (ttm)
-1.13B
Research Analysis: RPRX
Company Insights: RPRX
RPRX does not have Company Insights